Neuroendocrine transdifferentiation of prostate carcinoma cells and its prognostic significance

Romanian Journal of Morphology and Embryology

Volumn 51, Issue 1, 2010, Pages 7-12

  Marcu, Mǎdǎlina ^a   Radu, E ^a   Sajin, Maria ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Cell differentiation; Neuroendocrine cells; Prognosis; Prostate; Prostate cancer

Indexed keywords

TUMOR MARKER;

CANCER INVASION; CARCINOMA; CELL TRANSDIFFERENTIATION; EVALUATION; HUMAN; MALE; NEUROSECRETORY CELL; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROSTATE TUMOR; REVIEW; EVALUATION STUDY; PROSTATIC NEOPLASMS; TUMOR INVASION;

CARCINOMA; CELL TRANSDIFFERENTIATION; HUMANS; MALE; NEOPLASM INVASIVENESS; NEUROENDOCRINE CELLS; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77949356927     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P, Estimates of the cancer incidence and mortality in Europe in 2006, Ann Oncol, 2007, 18(3):581-592.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P, The Statistical Office of the European Communities (EUROSTAT) Dissemination Database, http://ec.europa.eu/eurostat, accessed in January 2009.
3. Shariat SF, Karakiewicz PI, Margulis V, Kattan MW, Inventory of prostate cancer predictive tools, Curr Opin Urol, 2008, 18(3):279.
4. Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, Gospadarowicz M, Kaplan RS, Miller DS, Montironi R, Pajak TF, Pollack A, Srigley JR, Yarbro JW, Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999, Arch Pathol Lab Med, 2000, 124(7):995-1000.
5. Isaacs JT, Prostate stem cells and benign prostatic hyperplasia, Prostate, 2008, 68(9):1025-1034.
6. Bonkhoff H, Remberger K, Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model, Prostate, 1996, 28(2):98-106.
7. Lesser B, Bruchovsky N, Effect of duration of the period after castration on the response of the rat ventral prostate to androgens, Biochem J, 1974, 142(2):429-431.
8. Evans GS, Chandler JA, Cell proliferation studies in the rat prostate: II. The effects of castration and androgen-induced regeneration upon basal and secretory cell proliferation, Prostate, 1987, 11(4):339-351.
9. Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S, Majumder P, McKeon F, Kantoff PW, Sellers WR, Loda M, p63 regulates commitment to the prostate cell lineage, Proc Natl Acad Sci U S A, 2005, 102(32):11355-11360.
10. Kurita T, Medina RT, Mills AA, Cunha GR, Role of p63 and basal cells in the prostate, Development, 2004, 131(20):4955-4964.
11. Leong KG, Wang BE, Johnson L, Gao WQ, Generation of a prostate from a single adult stem cell, Nature, 2008, 456(7223):804-808.
12. Collins AT, Habib FK, Maitland NJ, Neal DE, Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression, J Cell Sci, 2001, 114(Pt 21):3865-3872.
13. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT, CD133, a novel marker for human prostatic epithelial stem cells, J Cell Sci, 2004, 117(Pt 16):3539-3545.
14. Litvinov IV, Vander Griend DJ, Xu Y, Antony L, Dalrymple SL, Isaacs JT, Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells, Cancer Res, 2006, 66(17):8598-8607.
15. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT, The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells, Cancer Res, 2008, 68(23):9703-9711.
16. Sotomayor P, Godoy A, Smith GJ, Huss WJ, Oct4A is expressed by a subpopulation of prostate neuroendocrine cells, Prostate, 2009, 69(4):401-410.
17. Aumüller G, Leonhardt M, Janssen M, Konrad L, Bjartell A, Abrahamsson PA, Neurogenic origin of human prostate endocrine cells, Urology, 1999, 53(5):1041-1048.
18. di Sant'Agnese PA, De Mesy Jensen KL, Endocrineparacrine cells of the prostate and prostatic urethra: an ultrastructural study, Hum Pathol, 1984, 15(11):1034-1041.
19. Abrahamsson PA, Neuroendocrine cells in tumour growth of the prostate, Endocr Relat Cancer, 1999, 6(4):503-519.
20. Abrahamsson PA, Neuroendocrine differentiation in prostatic carcinoma, Prostate, 1999, 39(2):135-148.
21. Vashchenko N, Abrahamsson PA, Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities, Eur Urol, 2005, 47(2):147-155.
22. Krijnen JL, Janssen PJ, Ruizeveld de Winter JA, van Krimpen H, Schröder FH, van der Kwast TH, Do neuroendocrine cells in human prostate cancer express androgen receptor?, Histochemistry, 1993, 100(5):393-398.
23. Yang JC, Ok JH, Busby JE, Borowsky AD, Kung HJ, Evans CP, Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer, Cancer Res, 2009, 69(1):151-160.
24. Yuan TC, Veeramani S, Lin MF, Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells, Endocr Relat Cancer, 2007, 14(3):531-547.
25. Schalken JA, van Leenders G, Cellular and molecular biology of the prostate: stem cell biology, Urology, 2003, 62(5 Suppl 1):11-20.
26. Huang J, Yao JL, di Sant'Agnese PA, Yang Q, Bourne PA, Na Y, Immunohistochemical characterization of neuroendocrine cells in prostate cancer, Prostate, 2006, 66(13):1399-1406.
27. Xue Y, Verhofstad A, Lange W, Smedts F, Debruyne F, de la Rosette J, Schalken J, Prostatic neuroendocrine cells have a unique keratin expression pattern and do not express Bcl-2: cell kinetic features of neuroendocrine cells in the human prostate, Am J Pathol, 1997, 151(6):1759-1765.
28. Kasper S, Stem cells: The root of prostate cancer?, J Cell Physiol, 2008, 216(2):332-336.
29. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL, CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis, Br J Cancer, 2008, 98(4):756-765.
30. Lawson DA, Xin L, Lukacs RU, Cheng D, Witte ON, Isolation and functional characterization of murine prostate stem cells, Proc Natl Acad Sci U S A, 2007, 104(1):181-186.
31. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L, Bushnell T, Huang LS, Yang Q, Huang J, Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer, Prostate, 2009, 69(7):787-798.
32. Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, Ichikawa T, Fuse H, Neuroendocrine differentiation in the progression of prostate cancer, Int J Urol, 2009, 16(1):37-44.
33. Weinstein MH, Partin AW, Veltri RW, Epstein JI, Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy, Hum Pathol, 1996, 27(7):683-687.
34. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR; CapSURE Investigators, The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry, J Urol, 2004, 171(4):1393-1401.
35. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr, Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate, Cancer, 1997, 80(11):2109-2119.
36. May M, Siegsmund M, Hammermann F, Loy V, Gunia S, Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy, Scand J Urol Nephrol, 2007, 41(5):375-381.
37. Gunia S, Albrecht K, Koch S, Herrmann T, Ecke T, Loy V, Linke J, Siegsmund M, May M, Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability, World J Urol, 2008, 26(3):243-250.
38. Ahlegren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA, Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume, Urology, 2000, 56(6):1011-1015.
39. Revelos K, Petraki C, Scorilas A, Stefanakis S, Malovrouvas D, Alevizopoulos N, Kanellis G, Halapas A, Koutsilieris M, Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer, Anticancer Res, 2007, 27(5B):3651-3660.
40. Autorino R, Lamendola MG, De Luca G, De Sio M, Giuliano F, D'Armiento M, De Placido S, Conti P, Di Lorenzo G, Neuroendocrine immunophenotype as predictor of clinical recurrence in 110 patients with prostate cancer, Int J Immunopathol Pharmacol, 2007, 20(4):765-770.
41. Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW, Prognostic significance of plasma chromogranin A levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study, Urology, 2005, 66(2):386-391.
42. Grobholz R, Griebe M, Sauer CG, Michel MS, Trojan L, Bleyl U, Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma, Hum Pathol, 2005, 36(5):562-570.
43. Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, Russo L, Cracco C, Bollito E, Scarpa RM, Angeli A, Dogliotti L, Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease, Endocr Relat Cancer, 2005, 12(1):109-117.
44. McWilliam LJ, Manson C, George NJ, Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma, Br J Urol, 1997, 80(2):287-290.
45. Kamiya N, Suzuki H, Kawamura K, Imamoto T, Naya Y, Tochigi N, Kakuta Y, Yamaguchi K, Ishikura H, Ichikawa T, Neuroendocrine differentiation in stage D2 prostate cancers, Int J Urol, 2008, 15(5):423-428.
46. Shariff AH, Ather MH, Neuroendocrine differentiation in prostate cancer, Urology, 2006, 68(1):2-8.
47. Pienta KJ, Bradley D, Mechanisms underlying the development of androgen-independent prostate cancer, Clin Cancer Res, 2006, 12(6):1665-1671.
48. Harris WP, Mostaghel EA, Nelson PS, Montgomery B; Medscape, Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion, Nat Clin Pract Urol, 2009, 6(2):76-85.
49. Taplin ME, Drug insight: role of the androgen receptor in the development and progression of prostate cancer, Nat Clin Pract Oncol, 2007, 4(4):236-244.
50. Sasaki T, Komiya A, Suzuki H, Shimbo M, Ueda T, Akakura K, Ichikawa T, Changes in chromogranin A serum levels during endocrine therapy in metastatic prostate cancer patients, Eur Urol, 2005, 48(2):224-229; discussion 229-230.
51. Sciarra A, Di Silverio F, Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma, Urology, 2004, 63(3):523-527.
52. Tarle M, Ahel MZ, Kovacić K, Acquired neuroendocrinepositivity during maximal androgen blockade in prostate cancer patients, Anticancer Res, 2002, 22(4):2525-2529.
53. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N, Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy, Eur Urol, 2004, 45(5):586-592; discussion 592.